SCHEMBL4152740

SCHEMBL4152740

CC(C)(C(N)=O)C(C)(C)C(N)=O

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.43
ALOX15 P16050 1/20 0.43
BLM P54132 1/20 0.43
PMP22 Q01453 1/20 0.43
ALDH1A1 P00352 3/20 0.39
TDP1 Q9NUW8 2/20 0.39
OR51E2 Q9H255 1/20 0.39
MAPT P10636 2/20 0.38
KMT2A Q03164 1/20 0.38
ACHE P22303 1/20 0.36
TSHR P16473 1/20 0.35
GAA P10253 1/20 0.32
LDHA P00338 1/20 0.31
LDHB P07195 1/20 0.31
PTGS1 P23219 1/20 0.30
FDPS P14324 1/20 0.30
CRBN Q96SW2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11050625 0.87 TSHR (0.42) LMNAALOX15BLMPMP22ALDH1A1
SCHEMBL17550605 0.87 LMNA (0.41) LMNAALOX15BLMPMP22TDP1
SCHEMBL1090931 0.85 LMNA (0.38) LMNAALOX15BLMPMP22ALDH1A1
SCHEMBL25917062 0.82 LMNA (0.35) LMNAALOX15BLMPMP22ALDH1A1
SCHEMBL23128926 0.80
SCHEMBL27575205 0.79 TDP1 (0.33) LMNAALOX15BLMPMP22TDP1
SCHEMBL1053410 0.79 LMNA (0.33) LMNAALOX15BLMPMP22MAPT
SCHEMBL15128371 0.79 LMNA (0.33) LMNAALOX15BLMPMP22MAPT
Pivalamide SCHEMBL2484 0.78
SCHEMBL410733 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1052984-B1 ANTIBACTERIAL AGENTS VERNALIS OXFORD LTD (GB) 2004-05-12 EP claimed
US-20020165167-A1 Antibacterial agents BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) 2002-11-07 US claimed
US-10919835-B2 Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids Io Therapeutics, Inc. (US) 2021-02-16 US disclosed
EP-3725801-A2 AMINO DIACIDS CONTAINING PEPTIDE MODIFIERS Chemical & Biopharmaceutical Laboratories of Patras S.A. (GR) 2020-10-21 EP disclosed
US-20200190008-A1 COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-06-18 US disclosed
EP-2975620-B1 ALUMINUM ELECTROLYTIC CAPACITOR-USE ELECTROLYTIC SOLUTION AND ALUMINUM ELECTROLYTIC CAPACITOR USING SAME SANYO CHEMICAL IND LTD (JP) 2019-05-22 EP disclosed
CN-105190809-B Electrolyte for aluminum electrolytic capacitor and use its aluminium electrolutic capacitor 三洋化成工业株式会社 2017-12-12 CN disclosed
US-9793059-B2 Electrolytic solution for aluminum electrolytic capacitor and aluminum electrolytic capacitor using the same SANYO CHEMICAL INDUSTRIES, LTD. (JP) 2017-10-17 US disclosed
US-20160020036-A1 ELECTROLYTIC SOLUTION FOR ALUMINUM ELECTROLYTIC CAPACITOR AND ALUMINUM ELECTROLYTIC CAPACITOR USING THE SAME SANYO CHEMICAL INDUSTRIES, LTD. (JP) 2016-01-21 US disclosed
EP-2975620-A1 ALUMINUM ELECTROLYTIC CAPACITOR-USE ELECTROLYTIC SOLUTION AND ALUMINUM ELECTROLYTIC CAPACITOR USING SAME Sanyo Chemical Industries, Ltd. (JP) 2016-01-20 EP disclosed
CN-105190809-A Aluminum electrolytic capacitor-use electrolytic solution and aluminum electrolytic capacitor using same SANYO CHEMICAL IND LTD 2015-12-23 CN disclosed
WO-2001018072-A1 PROCESS FOR PRODUCING CROSS-LINKED POLYALLYLAMINE POLYMER THE DOW CHEMICAL COMPANY (US) 2001-03-15 WO disclosed
US-6180754-B1 CROSSLINKING POLYALLYLAMINE POLYMER IN SOLUTION THE DOW CHEMICAL COMPANY 2001-01-30 US disclosed
EP-1052984-A1 ANTIBACTERIAL AGENTS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 2000-11-22 EP disclosed
WO-1999039704-A1 ANTIBACTERIAL AGENTS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1999-08-12 WO disclosed
WO-1998007653-A1 CHIRAL HYDRIDE COMPLEXES ZEELAND CHEMICALS, INC. (US) 1998-02-26 WO disclosed
CN-1125939-A Process for producing acyloxybenzenesulfonic acid or salt thereof KAO CORP (JP) 1996-07-03 CN disclosed
US-4481373-A CATALYTIC OXIDATION OF OLEFINS IN PRESENCE OF TERTIARY AMINE OF AMIDE TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) 1984-11-06 US disclosed
US-4321198-A Polyimide derivatives having acetylenic amic acid groups PLASTICS ENGINEERING COMPANY (US) 1982-03-23 US disclosed
US-4168360-A CROSSLINKED, INSOLUBLE, INFUSIBLE COATINGS AND MOLDING MATERIALS PLASTICS ENGINEERING COMPANY (US) 1979-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200190008-A1 COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS RXRG, RXRB, RXRA LMNA 1712/4885ALOX15 1765/4885BLM 1448/4885
US-10919835-B2 Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids RXRG, RXRB, RXRA LMNA 1712/4885ALOX15 1765/4885BLM 1448/4885
US-20020165167-A1 Antibacterial agents CBR1, CBR3, SIGMAR1 LMNA 578/4885ALOX15 2137/4885BLM 2628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.